Charles Schwab
UBX

Charles Schwab’s Unity Biotechnology UBX Stock Holding History

Charles Schwab’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,595
Closed -$19K – 3568
2022
Q3 		$19K Hold
4,595
– – ﹤0.01% 3484
2022
Q2 		$26K Buy
+4,595
New +$38.3K ﹤0.01% 3501
2022
Q1 		– Sell
-1,259
Closed -$19K – 3620
2021
Q4 		$19K Hold
1,259
– – ﹤0.01% 3583
2021
Q3 		$38K Sell
1,259
-13,099
-91% -$462K ﹤0.01% 3477
2021
Q2 		$667K Sell
14,358
-8,282
-37% -$399K ﹤0.01% 3076
2021
Q1 		$1.36M Buy
22,640
+743
+3% +$50.7K ﹤0.01% 2757
2020
Q4 		$1.15M Buy
21,897
+919
+4% +$44.3K ﹤0.01% 2729
2020
Q3 		$726K Buy
20,978
+2,142
+11% +$136K ﹤0.01% 2765
2020
Q2 		$1.64M Buy
18,836
+2,095
+13% +$155K ﹤0.01% 2482
2020
Q1 		$972K Buy
16,741
+1,001
+6% +$63.1K ﹤0.01% 2496
2019
Q4 		$1.14M Buy
15,740
+690
+5% +$48.7K ﹤0.01% 2556
2019
Q3 		$919K Buy
15,050
+8,152
+118% +$577K ﹤0.01% 2600
2019
Q2 		$656K Buy
6,898
+746
+12% +$63.5K ﹤0.01% 2711
2019
Q1 		$499K Buy
6,152
+39
+0.6% +$4.42K ﹤0.01% 2771
2018
Q4 		$994K Buy
6,113
+3,840
+169% +$510K ﹤0.01% 2541
2018
Q3 		$371K Buy
2,273
+225
+11% +$37K ﹤0.01% 2943
2018
Q2 		$309K Buy
+2,048
New +$299K ﹤0.01% 2952

Other funds holding UBX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Charles Schwab's UBX Position: Q4 2022 in Review

Charles Schwab sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 4,595 shares — an estimated $19K sold.

Charles Schwab first reported a position in UBX in Q2 2018 and held it in 17 quarters. The position peaked at $1.64M in Q2 2020. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

  • Charles Schwab reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Charles Schwab sold 4,595 Unity Biotechnology shares in Q4 2022, an estimated $19K.
  • Charles Schwab first reported a position in Unity Biotechnology in Q2 2018 and held it in 17 quarters.
  • Charles Schwab's Unity Biotechnology position peaked at $1.64M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.